ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
U.S.-EU Tensions Rise After $140 Million Fine on Elon Musk’s X Platform 
CVS Health Signals Strong 2026 Profit Outlook Amid Turnaround Progress 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
U.S. Greenlights Nvidia H200 Chip Exports to China With 25% Fee 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the site's inauguration, confirmed plans for further investments in the coming years.
The Hyderabad facility, announced last year, aims to accelerate medicine development through cutting-edge technology. By year-end, it is expected to employ 2,000 people, with 300 already on board, according to Som Chattopadhyay, Amgen's national executive for India.
Amgen’s expansion aligns with India’s growing role as the “pharmacy of the world,” attracting global pharmaceutical giants. The company’s presence in Hyderabad coincides with the BioAsia conference, where key executives from Amgen, Eli Lilly (NYSE: LLY), Novartis (SIX: NOVN), and leading Indian pharma firms will participate.
The U.S. and India recently initiated talks for a trade deal to strengthen collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, highlighted Amgen’s expansion as a prime example of this partnership. However, potential U.S. tariffs on pharmaceutical imports—reportedly 25% or higher—could impact Indian drugmakers, as the U.S. remains their largest market.
With Amgen’s strategic investment, India’s biotech sector continues to gain global attention, reinforcing its position as a key hub for pharmaceutical innovation.
